218 related articles for article (PubMed ID: 34838486)
21. [Renovascular effects of antiangiogenic drugs].
Deray G; Janus N; Aloy B; Launay-Vacher V
Bull Cancer; 2016; 103(7-8):662-6. PubMed ID: 27318610
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
Lacal PM; Graziani G
Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
Snider KL; Maitland ML
Target Oncol; 2009 Apr; 4(2):67-76. PubMed ID: 19373440
[TBL] [Abstract][Full Text] [Related]
24. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
25. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.
Minion LE; Tewari KS
Expert Rev Anticancer Ther; 2017 Mar; 17(3):191-198. PubMed ID: 27748633
[TBL] [Abstract][Full Text] [Related]
26. Vascular toxicity associated with anti-angiogenic drugs.
Neves KB; Montezano AC; Lang NN; Touyz RM
Clin Sci (Lond); 2020 Sep; 134(18):2503-2520. PubMed ID: 32990313
[TBL] [Abstract][Full Text] [Related]
27. Targeting Angiogenesis in Colorectal Carcinoma.
Lopez A; Harada K; Vasilakopoulou M; Shanbhag N; Ajani JA
Drugs; 2019 Jan; 79(1):63-74. PubMed ID: 30617958
[TBL] [Abstract][Full Text] [Related]
28. Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response.
Geindreau M; Ghiringhelli F; Bruchard M
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34064508
[TBL] [Abstract][Full Text] [Related]
29. [Vascular and renal effects of anti-angiogenic therapy].
Halimi JM; Azizi M; Bobrie G; Bouché O; Deray G; des Guetz G; Lecomte T; Levy B; Mourad JJ; Nochy D; Oudard S; Rieu P; Sahali D
Nephrol Ther; 2008 Dec; 4(7):602-15. PubMed ID: 19027389
[TBL] [Abstract][Full Text] [Related]
30. [Novelties in the treatment for advanced renal-cell cancer].
Maráz A
Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
[TBL] [Abstract][Full Text] [Related]
31. [Nephrotoxicity--proteinuria and hypertension--].
Ando M
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1649-53. PubMed ID: 18931564
[TBL] [Abstract][Full Text] [Related]
32. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.
Zhu Y; Zhang T; Xu G; Peng L
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD011160. PubMed ID: 27977064
[TBL] [Abstract][Full Text] [Related]
33. Anti-angiogenesis therapies: their potential in cancer management.
Eichholz A; Merchant S; Gaya AM
Onco Targets Ther; 2010 Jun; 3():69-82. PubMed ID: 20616958
[TBL] [Abstract][Full Text] [Related]
34. Challenges facing antiangiogenesis therapy: The significant role of hypoxia-inducible factor and MET in development of resistance to anti-vascular endothelial growth factor-targeted therapies.
Mahdi A; Darvishi B; Majidzadeh-A K; Salehi M; Farahmand L
J Cell Physiol; 2019 May; 234(5):5655-5663. PubMed ID: 30515806
[TBL] [Abstract][Full Text] [Related]
35. Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?
Jin K; Shen Y; He K; Xu Z; Li G; Teng L
Clin Transl Oncol; 2010 Aug; 12(8):526-32. PubMed ID: 20709650
[TBL] [Abstract][Full Text] [Related]
36. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
Ferrara N
Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
[TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
Takahashi S
Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
[TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Rini BI
Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
[TBL] [Abstract][Full Text] [Related]
39. [Angiogenesis and renal cell carcinoma].
Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
[TBL] [Abstract][Full Text] [Related]
40. VEGF inhibition, hypertension, and renal toxicity.
Hayman SR; Leung N; Grande JP; Garovic VD
Curr Oncol Rep; 2012 Aug; 14(4):285-94. PubMed ID: 22544560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
